Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Cyclosporine

FDA-approved product (injectable, injection), marketed as Cequa, Cyclosporine, Gengraf and 6 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Cyclosporine
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Conjunctivitis
  • Corneal disease
  • Eye disease
  • Immune system disease
  • Inflammation
  • Keratitis
  • Keratoconjunctivitis
  • Psoriasis
  • Rheumatoid arthritis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Calcineurin inhibitors; Other ophthalmologicals
FDA pharmacologic class
Calcineurin Inhibitor Immunosuppressant FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli, K. pneumoniae and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA61.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli53.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae56.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis50.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Cyclosporine in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Cyclosporine with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Donor Umbilical Cord Blood Natural Killer Cells, Aldesleukin and Umbilical Cord Blood Transplant in Patients With Refractory Hematologic Cancers.

    NCT00354172 · start 2006-02

    Registered record
    Registry ID
    NCT00354172
    Conditions
    Leukemia; Myelodysplastic Syndromes
    Interventions
    aldesleukin; filgrastim; natural killer cell (NK) therapy; cyclophosphamide; cyclosporine; fludarabine phosphate; methylprednisolone; mycophenolate mofetil; Umbilical Cord Blood Transplantation (UCBT); Total body irradiation (TBI)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2006-02
    Completion
    2008-08
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLeukemia; Myelodysplastic Syndromes
    Interventionaldesleukin; filgrastim; natural killer cell (NK) therapy; cyclophosphamide +6 more
    PhasePhase 2
    Registry statusTerminated

  • Rapamycin for Immunosuppression and B Cell Modulation Post Stem Cell Transplant for Acute Lymphoblastic Leukemia (ALL)

    NCT00795886 · start 2005-08

    Registered record
    Registry ID
    NCT00795886
    Conditions
    Acute Lymphoblastic Leukemia
    Interventions
    RAPAMYCIN
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2005-08
    Completion
    2010-03
    Enrolment
    63

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Lymphoblastic Leukemia
    InterventionRAPAMYCIN
    PhasePhase 2
    Registry statusCompleted

  • Efficacy and Safety of Everolimus With Enteric-Coated Mycophenolate Sodium (EC-MPS) in a Cyclosporine Microemulsion-free Regimen Compared to Standard Therapy in de Novo Renal Transplant Patients

    NCT00154310 · start 2005-06

    Registered record
    Registry ID
    NCT00154310
    Conditions
    Renal Transplantation
    Interventions
    Everolimus; Cyclosporine; Enteric-coated mycophenolate sodium; Corticosteroids
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2005-06
    Completion
    2008-09
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRenal Transplantation
    InterventionEverolimus; Cyclosporine; Enteric-coated mycophenolate sodium; Corticosteroids
    PhasePhase 4
    Registry statusCompleted

  • Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer

    NCT00118352 · start 2005-03

    Registered record
    Registry ID
    NCT00118352
    Conditions
    Acute Undifferentiated Leukemia; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Myeloid Leukemia in Remission; Adult Nasal Type Extranodal NK/T-cell Lymphoma; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative; Childhood Acute Lymphoblastic Leukemia in Remission; Childhood Acute Myeloid Leukemia in Remission; Childhood Burkitt Lymphoma; Childhood Chronic Myelogenous Leukemia; Childhood Diffuse Large Cell Lymphoma; Childhood Immunoblastic Large Cell Lymphoma; Childhood Myelodysplastic Syndromes; Childhood Nasal Type Extranodal NK/T-cell Lymphoma; Chronic Myelomonocytic Leukemia; Chronic Phase Chronic Myelogenous Leukemia; Cutaneous B-cell Non-Hodgkin Lymphoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Hepatosplenic T-cell Lymphoma; Intraocular Lymphoma; Juvenile Myelomonocytic Leukemia; Mast Cell Leukemia; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; N
    Interventions
    alemtuzumab; total-body irradiation; fludarabine phosphate; cyclosporine; mycophenolate mofetil; allogeneic hematopoietic stem cell transplantation; peripheral blood stem cell transplantation; graft versus host disease prophylaxis/therapy; laboratory biomarker analysis
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2005-03
    Completion
    2015-05-26
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Undifferentiated Leukemia; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Myeloid Leukemia in Remission; Adult Nasal Type Extranodal NK/T-cell Lymphoma +21 more
    Interventionalemtuzumab; total-body irradiation; fludarabine phosphate; cyclosporine +5 more
    PhasePhase 2
    Registry statusCompleted

  • Flu/TBI in Treating Patients Not Responding to Previous Hormone Therapy

    NCT00242931 · start 2005-01

    Registered record
    Registry ID
    NCT00242931
    Conditions
    Prostate Cancer
    Interventions
    Nonmyeloablative stem cell conditioning regimen
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2005-01
    Completion
    2008-03
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionNonmyeloablative stem cell conditioning regimen
    PhasePhase 2
    Registry statusWithdrawn

  • Withdrawal of Steroids, Cyclosporine A Dose Reduction and Switch to Mycophenolatmofetile After Heart Transplantation

    NCT00359658 · start 2004-11

    Registered record
    Registry ID
    NCT00359658
    Conditions
    Heart Transplantation
    Interventions
    prednisolon; Mycophenolatmofetile; Cyclosporin A
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2004-11
    Completion
    2008-06
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Transplantation
    Interventionprednisolon; Mycophenolatmofetile; Cyclosporin A
    PhaseNot applicable
    Registry statusCompleted

  • Combination Chemotherapy and Cyclosporine Followed by Focal Therapy for Bilateral Retinoblastoma

    NCT00110110 · start 2004-06

    Registered record
    Registry ID
    NCT00110110
    Conditions
    Retinoblastoma
    Interventions
    filgrastim; Carboplatin; Cyclosporine; Etoposide; vincristine sulfate; cryosurgery; laser therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2004-06
    Completion
    2024-12-31
    Enrolment
    71

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRetinoblastoma
    Interventionfilgrastim; Carboplatin; Cyclosporine; Etoposide +3 more
    PhasePhase 2
    Registry statusUnknown

  • Study to Evaluate the Combination of Enteric-coated Mycophenolate Sodium (EC-MPS), Basiliximab, and C2-monitored Cyclosporine in de Novo Renal Transplant Recipients at Potential High Risk of Delayed Graft Function (DGF)

    NCT00154232 · start 2004-06

    Registered record
    Registry ID
    NCT00154232
    Conditions
    Renal Transplantation
    Interventions
    Enteric-Coated Mycophenolate Sodium (EC-MPS)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2004-06
    Completion
    Not recorded
    Enrolment
    46

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRenal Transplantation
    InterventionEnteric-Coated Mycophenolate Sodium (EC-MPS)
    PhasePhase 4
    Registry statusCompleted

  • Study of Therapeutic Options for Subjects Discontinuing Efalizumab and Experiencing Disease Recurrence

    NCT01079988 · start 2004-02

    Registered record
    Registry ID
    NCT01079988
    Conditions
    Psoriasis
    Interventions
    Cyclosporins; Retinoids; Systemic corticosteroids; Methotrexate; Systemic corticosteroids/methotrexate
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2004-02
    Completion
    2005-04
    Enrolment
    41

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPsoriasis
    InterventionCyclosporins; Retinoids; Systemic corticosteroids; Methotrexate +1 more
    PhasePhase 4
    Registry statusCompleted

  • Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)

    NCT00075829 · start 2003-12

    Registered record
    Registry ID
    NCT00075829
    Conditions
    Multiple Myeloma
    Interventions
    One Autologous Transplant; Non-Myeloablative Allogeneic Transplant; Second Autologous Transplant; Thalidomide; Dexamethasone; Observation
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2003-12
    Completion
    2013-03
    Enrolment
    710

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultiple Myeloma
    InterventionOne Autologous Transplant; Non-Myeloablative Allogeneic Transplant; Second Autologous Transplant; Thalidomide +2 more
    PhasePhase 3
    Registry statusCompleted

  • Thymus Transplantation With Immunosuppression

    NCT00579709 · start 2002-07

    Registered record
    Registry ID
    NCT00579709
    Conditions
    DiGeorge Syndrome; DiGeorge Anomaly; Complete DiGeorge Anomaly; Complete DiGeorge Syndrome
    Interventions
    Thymus Tissue for Transplantation
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2002-07
    Completion
    2019-12
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiGeorge Syndrome; DiGeorge Anomaly; Complete DiGeorge Anomaly; Complete DiGeorge Syndrome
    InterventionThymus Tissue for Transplantation
    PhasePhase 1
    Registry statusCompleted

  • Combined Bone Marrow Transplantation (BMT) and Renal Transplant for Multiple Myeloma (MM) With End Stage Renal Disease (ESRD)

    NCT00854139 · start 2001-08

    Registered record
    Registry ID
    NCT00854139
    Conditions
    Multiple Myeloma; End Stage Renal Disease
    Interventions
    Cyclophosphamide, anti-thymocyte globulin; Kidney transplant; Thymic irradiation; Bone marrow transplant from a related donor
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2001-08
    Completion
    2014-07
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultiple Myeloma; End Stage Renal Disease
    InterventionCyclophosphamide, anti-thymocyte globulin; Kidney transplant; Thymic irradiation; Bone marrow transplant from a related donor
    PhasePhase 1
    Registry statusCompleted

  • Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or Nilotinib

    NCT00036738 · start 2001-07-13

    Registered record
    Registry ID
    NCT00036738
    Conditions
    Adult Acute Lymphoblastic Leukemia in Remission; Adult B Acute Lymphoblastic Leukemia With t(9; 22)(q34.1; q11.2); BCR-ABL1; Blastic Phase; Childhood Acute Lymphoblastic Leukemia in Remission; Childhood B Acute Lymphoblastic Leukemia With t(9; 22)(q34.1; q11.2); BCR-ABL1; Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Chronic Phase of Disease; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Childhood Acute Lymphoblastic Leukemia; Recurrent Disease
    Interventions
    Cyclosporine; Dasatinib; Fludarabine Phosphate; Imatinib Mesylate; Mycophenolate Mofetil; Nilotinib; Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation; Peripheral Blood Stem Cell Transplantation; Therapeutic Allogeneic Lymphocytes; Total-Body Irradiation
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2001-07-13
    Completion
    2018-05
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdult Acute Lymphoblastic Leukemia in Remission; Adult B Acute Lymphoblastic Leukemia With t(9; 22)(q34.1; q11.2) +12 more
    InterventionCyclosporine; Dasatinib; Fludarabine Phosphate; Imatinib Mesylate +6 more
    PhasePhase 2
    Registry statusCompleted

  • Study Comparing the Safety and Efficacy of Belatacept With That of Cyclosporine in Patients With a Transplanted Kidney

    NCT00035555 · start 2001-03

    Registered record
    Registry ID
    NCT00035555
    Conditions
    Graft Rejection; Kidney Transplantation; Renal Transplantation
    Interventions
    Belatacept; Cyclosporine; Mycophenolate mofetil (MMF); Corticosteroids
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2001-03
    Completion
    2012-07
    Enrolment
    230

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGraft Rejection; Kidney Transplantation; Renal Transplantation
    InterventionBelatacept; Cyclosporine; Mycophenolate mofetil (MMF); Corticosteroids
    PhasePhase 2
    Registry statusCompleted

  • Antithymocyte Globulin and Cyclosporine in Treating Patients With Myelodysplastic Syndrome

    NCT00004208 · start 2000-08

    Registered record
    Registry ID
    NCT00004208
    Conditions
    Myelodysplastic Syndromes
    Interventions
    ATG + CSA; Supportive care
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2000-08
    Completion
    2011-10
    Enrolment
    86

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMyelodysplastic Syndromes
    InterventionATG + CSA; Supportive care
    PhasePhase 3
    Registry statusCompleted